Medline Inc (MDLN) Stock Forecast & Price Target

Medline is supported by a differentiated vertically integrated model that combines roughly 190,000 Medline-branded products, about 150,000 third-party products, more than 30 manufacturing facilities, and a fleet of over 2,000 delivery trucks, giving it scale and control across the U.S. med-surg supply chain. Its 1,300+ Prime Vendor relationships, $5 billion of identified Medline Brand conversion opportunity, and 2026 new business momentum, including $659 million of first-half signings and 11.6% year-over-year net sales growth to $7.69 billion in Q2 2026, point to durable demand and meaningful margin expansion as lower-margin Supply Chain revenue converts to higher-margin proprietary products. Near-term EBITDA pressure from $200 million of disclosed costs, tariffs, and the Tracy fire appears transitory, while strong cash flow and a growing installed base should help lift returns on capital and economic profit over time.

Medline is facing a weaker fundamental backdrop because its conservative earnings reporting still leaves exposure to roughly $89 million of revenue headwind in 2Q:26, tariff uncertainty, and possible margin pressure from changing manufacturers, locations, and imported product costs. The June 11, 2026 Tracy fire further exposed operational fragility, producing a $336 million pre-insurance loss, cutting Q2 net income 58.3% to $139 million, and adding another $50 million to $100 million of costs in the second half while reducing 2026 adjusted EBITDA guidance to $3.3 billion to $3.4 billion. Beyond the incident, Medline’s heavy debt load, capital-intensive distribution model, and reliance on hospital spending make it vulnerable to BBBA-related Medicaid cuts, tighter budgets, intense competition, and slower de-leveraging.